Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Rating of “Moderate Buy” by Brokerages

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $106.8462.

SLNO has been the subject of several research reports. TD Cowen cut their price objective on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Zacks Research downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Wells Fargo & Company lowered their price target on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. HC Wainwright dropped their price target on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Finally, Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research note on Monday, January 12th.

Soleno Therapeutics Stock Down 8.1%

Shares of NASDAQ SLNO opened at $33.76 on Monday. The company’s 50-day simple moving average is $40.74 and its 200-day simple moving average is $50.93. Soleno Therapeutics has a 52-week low of $32.63 and a 52-week high of $90.32. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 146.79 and a beta of -3.16. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Equities analysts predict that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

A number of hedge funds have recently modified their holdings of SLNO. Wellington Management Group LLP lifted its stake in shares of Soleno Therapeutics by 272.3% in the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock worth $156,298,000 after buying an additional 1,691,057 shares in the last quarter. Braidwell LP acquired a new position in Soleno Therapeutics during the third quarter worth about $86,662,000. Janus Henderson Group PLC grew its stake in Soleno Therapeutics by 18.5% during the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock valued at $332,302,000 after acquiring an additional 1,122,015 shares in the last quarter. Invesco Ltd. grew its stake in Soleno Therapeutics by 132.3% during the 3rd quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock valued at $101,435,000 after acquiring an additional 854,551 shares in the last quarter. Finally, Commodore Capital LP raised its holdings in Soleno Therapeutics by 121.3% in the 3rd quarter. Commodore Capital LP now owns 1,350,000 shares of the company’s stock valued at $91,260,000 after acquiring an additional 740,000 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Recent operational data: Soleno reported quarterly results on Feb. 25 that beat consensus — $0.80 EPS vs. $0.64 estimate and revenue roughly $91.7M vs. ~$88.6M — a near‑term fundamental positive that may temper downside if litigation risk abates.
• Negative Sentiment: Class action filings allege Soleno misled investors about the integrity, safety and results of its DCCR Phase 3 program, citing the company’s Nov. 5, 2025 disclosures; the Hagens Berman notice is a representative filing. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple national plaintiff firms (Robbins Geller, Schall, Kessler Topaz, Rosen, Glancy Prongay, Levi & Korsinsky, etc.) are actively soliciting clients and reminding investors of the May 5, 2026 lead‑plaintiff deadline, increasing the likelihood of consolidated litigation and potential settlement exposure. Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
• Negative Sentiment: Allegations across notices include claims of concealed safety issues, material misstatements/omissions about trial conduct and efficacy, and even charges of “sham” trials — outcomes that, if substantiated, could lead to regulatory inquiry, management distraction, legal costs and damages payments.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.